



Media Release

22 July 2019

Ash Attia joins BVT as CEO

Bionic Vision Technologies Pty Ltd (BVT) today announced that Ash Attia has joined the company as its Chief Executive Officer (CEO).

Ash Attia has over 30 years of senior executive management experience in implantable devices and biotechnology. Most recently, Ash held the position of Vice President Asia Pacific, the Middle East and Israel, at TransMedics Inc. Prior to this, Ash held Vice President and Managing Director roles within several other major Australian and International medtech organizations such as Thoratec, St Jude Medical, Micromed, Syncardia, Ventracor, Biotronik, SulzerMedica and Teletronics.

Ash has extensive experience in medical technology commercialization, general management, research and development, marketing, market entry strategies, regulatory and reimbursement across multiple geographies (USA, Asia Pacific and Europe). He is also a Fellow of the Australian Institute of Company Directors and has extensive governance experience being a Non-Executive Director on the board of ASX-listed Company DorsaVi for over 10 years.

Ash holds a Masters of Science in Biomedical and Electronics Engineering from the New Jersey Institute of Technology in conjunction with the University of Medicine and Dentistry, New Jersey, USA. Ash also holds postgraduate qualifications in business and general management.

About Bionic Vision Technologies Pty Ltd (BVT)

Bionic Vision Technologies Pty Ltd (BVT) is an Australian medical device company that aims to preserve and restore a sense of vision by developing a range of best in class technologies to address degenerative retinal conditions. BVT is commercialising the technologies developed by Bionic Vision Australia (BVA), a consortium of leading universities and research institutes funded by the Australian Research Council from 2010 to 31 December 2016.

In April 2017, BVT received A\$23.6 million from Hong Kong-based State Path Capital and China Huarong International Holdings. The funds enabled BVT to accelerate development and clinical studies. Consortium members collaborating on the trial include the Bionics Institute, Centre for Eye Research Australia, CSIRO's Data 61, the University of Melbourne, and The Royal



BIONIC VISION
TECHNOLOGIES

Victorian Eye and Ear Hospital. BVT will seek further capital to complete regulatory trials and technology development.

How the Bionic Vision Technologies (BVT) Pty Ltd bionic eye works

The BVT developed bionic eye consists of implanted and body worn components. The patient wears glasses with a small video camera mounted on the side. The live feed from the camera is processed and transmitted via an implanted microchip to an electrode array placed in a naturally occurring pocket behind the retina, called the suprachoroidal space. The electrodes stimulate remaining cells in the retina, to generate spots of light that give a patient a sense of vision.

For further information, please contact:

Adrian Oates, COO M: 0409 434 299 E: adrian.oates@bionicvis.com
